摘要
目的探讨分析凯西莱（硫普罗宁）治疗肝硬化、改善肝脏功能的临床疗效。方法将100例不同病因确诊肝硬化患者随机分为治疗组50例，对照组50例。对照组应用常规综合治疗，治疗组在此基础上再加用凯西莱（硫普罗宁）0．2g静脉点滴，1次，d，疗程1个月。疗程结束时，比较两组患者肝功能及血清肝纤维化等指标变化。结果治疗组患者肝功能指标丙氨酸转移酶（ALT）、天门冬氨酸转移酶（AST）、总胆红素（TBil）、白蛋白（A）及血清肝纤维化指标：透明质酸（HA）、III型前胶原（PC—III）、IV型胶原（IV—C）、层粘蛋白（LN）改善与对照组比较，除ALT、LN指标差异无显著性意义（P均〉0．05）外，余指标间差异均有显著性（P〈0．05或〈0．01）。结论凯西莱（硫普罗宁）能改善肝硬化患者肝功能，同时有一定的促进肝细胞再生作用，对肝纤维化形成也有一定抑制作用，且不良反应少，疗效显著。
Objective To explore the efficacy of tiopronin in the treatment of hepatic cirrhosis. Methods 100 patients with hepatic cirrhosis were randomly assigned to receive conventional therapies （ 50 patients, control group ）, or intravenous tiopronin of 200rag once daily for one month in addition to conventional treatment （ 50 patients, study group ）. After completion of therapy, the changes in hepatic function and serum indexes for liver fibrosis were compared between the two groups. Results There were were significant differences in levels of AST, TBil, albumin, hyaluronic acid, PC-m, and IV-C between the study group and the control group （ P〈 0.05 or P〈 0.01 ）~ while levels of ALT and laminin did not differ significantly （ P 〉 0.05 ）. Conclusions Tiopronin can improve hepatic function in patients with cirrhosis and plays certain role in accelerating the regeneration of hepatic cells and in inhibiting the formation of liver fibrosis. It has a significant efficacy but fewer adverse reactions.
出处
《国际医药卫生导报》
2011年第23期2903-2905,共3页
International Medicine and Health Guidance News
